Commercialization Anticipated in 2016
KANSAS CITY, KA, USA I June 26, 2015 I Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, today announced positive results from its pivotal field effectiveness study of capromorelin (AT-002), the company’s innovative therapeutic for appetite stimulation in dogs. Capromorelin is a small molecule that mimics ghrelin, the naturally occurring hormone that stimulates appetite, increases body weight and increases serum growth hormone levels.
In the pivotal field effectiveness study, dogs receiving a 3 mg/kg daily oral dose of capromorelin for four days demonstrated statistically significant increases in appetite compared to placebo (p<0.05). The study was a randomized, masked, placebo controlled multi-site study that enrolled over 200 inappetent dogs. Appetite was assessed with an owner questionnaire comparing appetite at baseline to appetite after four days of treatment.
Ernst Heinen, DVM, Ph.D., Chief Development Officer for Aratana Therapeutics, stated, “The results from the pivotal field study demonstrate that capromorelin clearly stimulated appetite in client-owned dogs. We believe it could be a first-in-class approved drug for treating inappetence in dogs.”
The positive data from the pivotal field effectiveness study adds to the robust safety and efficacy data that has been generated in prior studies of capromorelin in dogs.
The pivotal field effectiveness study data are the final piece of the Effectiveness Technical Section that Aratana plans to submit to the Food and Drug Administration’s Center for Veterinary Medicine as the Company pursues marketing approval for capromorelin. Based on current timelines for the FDA approval process, Aratana anticipates commencing commercialization of capromorelin for treatment of inappetence in dogs in 2016.
About Aratana Therapeutics
Aratana Therapeutics is a pet therapeutics company focused on licensing, developing and commercializing innovative biopharmaceutical products for companion animals. Aratana believes that it can leverage the investment in the human biopharmaceutical industry to bring therapeutics to pets in a capital and time efficient manner. The company’s pipeline includes therapeutic candidates targeting pain, inappetence, cancer, viral diseases, allergy and other serious medical conditions. Aratana believes the development and commercialization of these therapeutics will permit veterinarians and pet owners to manage pets’ medical needs safely and effectively, resulting in longer and improved quality of life for pets. For more information, please visit www.aratana.com.
SOURCE: Aratana Therapeutics
Post Views: 295
Commercialization Anticipated in 2016
KANSAS CITY, KA, USA I June 26, 2015 I Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, today announced positive results from its pivotal field effectiveness study of capromorelin (AT-002), the company’s innovative therapeutic for appetite stimulation in dogs. Capromorelin is a small molecule that mimics ghrelin, the naturally occurring hormone that stimulates appetite, increases body weight and increases serum growth hormone levels.
In the pivotal field effectiveness study, dogs receiving a 3 mg/kg daily oral dose of capromorelin for four days demonstrated statistically significant increases in appetite compared to placebo (p<0.05). The study was a randomized, masked, placebo controlled multi-site study that enrolled over 200 inappetent dogs. Appetite was assessed with an owner questionnaire comparing appetite at baseline to appetite after four days of treatment.
Ernst Heinen, DVM, Ph.D., Chief Development Officer for Aratana Therapeutics, stated, “The results from the pivotal field study demonstrate that capromorelin clearly stimulated appetite in client-owned dogs. We believe it could be a first-in-class approved drug for treating inappetence in dogs.”
The positive data from the pivotal field effectiveness study adds to the robust safety and efficacy data that has been generated in prior studies of capromorelin in dogs.
The pivotal field effectiveness study data are the final piece of the Effectiveness Technical Section that Aratana plans to submit to the Food and Drug Administration’s Center for Veterinary Medicine as the Company pursues marketing approval for capromorelin. Based on current timelines for the FDA approval process, Aratana anticipates commencing commercialization of capromorelin for treatment of inappetence in dogs in 2016.
About Aratana Therapeutics
Aratana Therapeutics is a pet therapeutics company focused on licensing, developing and commercializing innovative biopharmaceutical products for companion animals. Aratana believes that it can leverage the investment in the human biopharmaceutical industry to bring therapeutics to pets in a capital and time efficient manner. The company’s pipeline includes therapeutic candidates targeting pain, inappetence, cancer, viral diseases, allergy and other serious medical conditions. Aratana believes the development and commercialization of these therapeutics will permit veterinarians and pet owners to manage pets’ medical needs safely and effectively, resulting in longer and improved quality of life for pets. For more information, please visit www.aratana.com.
SOURCE: Aratana Therapeutics
Post Views: 295
